✦ LIBER ✦

Neuropsychiatric effects of Parkinson's disease treatment

✍ Scribed by Sallyanne Aarons; Carmelle Peisah; Chanaka Wijeratne

Book ID: 117964029
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 102 KB
Volume: 31
Category: Article
ISSN: 1440-6381
DOI: 10.1111/j.1741-6612.2012.00632.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Neuropsychiatric Aspects of Parkinson’s

Neuropsychiatric Aspects of Parkinson’s Disease

✍ Laura Marsh 📂 Article 📅 2000 🏛 American Psychiatric Publishing Inc 🌐 English ⚖ 140 KB

Neuropsychiatric aspects of parkinson’s

Neuropsychiatric aspects of parkinson’s disease

✍ Dag Aarsland; Karen Karlsen 📂 Article 📅 1999 🏛 Springer 🌐 English ⚖ 378 KB

Drug treatments for the neuropsychiatric

Drug treatments for the neuropsychiatric complications of Parkinson’s disease

✍ Connolly, Barbara S; Fox, Susan H 📂 Article 📅 2012 🏛 Expert Reviews 🌐 English ⚖ 920 KB

Cognitive and neuropsychiatric effects o

Cognitive and neuropsychiatric effects of subthalamotomy for Parkinson’s disease

✍ Scott Bickel; Lazaro Alvarez; Raul Macias; Nancy Pavon; Miraida Leon; Cristina F 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 294 KB

Neuropsychiatric symptoms in Parkinson's

Neuropsychiatric symptoms in Parkinson's disease

✍ Dag Aarsland; Laura Marsh; Anette Schrag 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 1 views

## Abstract Neuropsychiatric symptoms are common in Parkinson's disease, even at the earliest stages, and have important consequences for quality of life and daily functioning, are associated with increased carer burden and increased risk for nursing home admission. In addition to cognitive impairm

Neuropsychiatric symptoms in Parkinson's

Neuropsychiatric symptoms in Parkinson's disease

✍ Joseph Friedman 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 51 KB 👁 1 views

In their excellent review of neuropsychiatric problems in Parkinson's disease (PD), 1 the authors made one small error but more importantly raised an interesting question about drug trials. Also, as they wrote their article, both melperone (personal communication) and pimavanserin, 2 subjected to ra